Supplementary information: Systematic Multiomics Analysis of C1QBP mRNA Expression Alterations and Its Relevance of Clinical Outcomes in Cancers Subbroto Kumar Saha1, Kyung Eun Kim2, S.M. Riazul Islam3, Ssang-Goo Cho1,* and Minchan Gil1,* 1 Department of Stem Cell and Regenerative Biotechnology, Incurable Disease Animal Model & Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul, 05029 Republic of Korea; [email protected] (S.K.S.), [email protected] (S-G. C), [email protected] (M.G.) 2 Department of Cosmetic Sciences, Sookmyung Women's University, Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul 04310, Republic of Korea; [email protected] 3 Department of Computer Science and Engineering, Sejong University, 209, Neungdong-ro, Gwangjin-gu, Seoul, 05006, Republic of Korea; [email protected] (S.M.R.I.) * Correspondence: [email protected]; [email protected]; Tel.: +82-10-2773-0173 (M.G.) +82-2-450- 4207 (S.-G.C.); Fax.: +82-2-444-4207 (S.-G.C. and M.G.) Supplementary Table S1. Datasets of C1QBP expression in breast cancer (Oncomine database). Normal Fold p- Rank Dataset Tumor (Cases) t-Test (Cases) change value (%) 2.82E- Curtis Breast (144) Tubular Breast Carcinoma (67) 1.45 9.507 16 8 3.94E- Breast (144) Breast Carcinoma (14) 1.585 4.275 04 9 1.67E- Breast (144) Invasive Breast Carcinoma (21) 1.382 4.217 04 11 Invasive Ductal Breast Carcinoma 9.46E- Breast (144) (1,556) 1.359 14.336 34 15 Invasive Ductal and Invasive 1.06E- Breast (144) Lobular Breast Carcinoma (90) 1.326 7.262 11 15 Ductal Breast Carcinoma in Situ 5.00E- Breast (144) (10) 1.393 3.215 03 15 1.70E- Breast (144) Mucinous Breast Carcinoma (46) 1.399 5.779 07 16 7.12E- Breast (144) Medullary Breast Carcinoma (32) 1.445 4.28 05 18 Turash Ductal Breast Invasive Ductal Breast Carcinoma vili Cell (10) (5) -1.584 -2.25 0.022 7 1.20E- Finak Breast (6) Invasive Breast Carcinoma (53) -2.716 -9.253 11 15 Supplementary Table S2. Survival analyses of C1QBP in breast cancer (PrognoScan database). COX p- HR [95% CI- DATASET ENDPOINT ARRAY TYPE PROBE ID N VALUE low CI-upp] Distant Metastasis Free HG- 0.52 [0.12 - GSE19615 208910_s_at 115 0.371956 Survival U133_Plus_2 2.20] Distant Metastasis Free HG- 0.35 [0.08 - GSE19615 214214_s_at 115 0.169939 Survival U133_Plus_2 1.57] HG- 1.14 [0.82 - GSE12276 Relapse Free Survival 214214_s_at 204 0.43914 U133_Plus_2 1.59] HG- 1.10 [0.81 - GSE12276 Relapse Free Survival 208910_s_at 204 0.537201 U133_Plus_2 1.50] GSE6532- HG- 1.24 [0.59 - Relapse Free Survival 214214_s_at 87 0.565589 GPL570 U133_Plus_2 2.62] GSE6532- HG- 1.30 [0.65 - Relapse Free Survival 208910_s_at 87 0.462749 GPL570 U133_Plus_2 2.60] GSE6532- Distant Metastasis Free HG- 1.24 [0.59 - 214214_s_at 87 0.565589 GPL570 Survival U133_Plus_2 2.62] GSE6532- Distant Metastasis Free HG- 1.30 [0.65 - 208910_s_at 87 0.462749 GPL570 Survival U133_Plus_2 2.60] HG- 0.68 [0.25 - GSE9195 Relapse Free Survival 214214_s_at 77 0.439715 U133_Plus_2 1.83] HG- 0.66 [0.29 - GSE9195 Relapse Free Survival 208910_s_at 77 0.314056 U133_Plus_2 1.49] Distant Metastasis Free HG- 0.76 [0.30 - GSE9195 208910_s_at 77 0.566883 Survival U133_Plus_2 1.94] Distant Metastasis Free HG- 0.83 [0.27 - GSE9195 214214_s_at 77 0.746708 Survival U133_Plus_2 2.58] Distant Metastasis Free 0.77 [0.38 - GSE12093 HG-U133A 208910_s_at 136 0.468174 Survival 1.57] Distant Metastasis Free 1.50 [0.55 - GSE12093 HG-U133A 214214_s_at 136 0.423397 Survival 4.07] Distant Metastasis Free 0.80 [0.36 - GSE11121 HG-U133A 208910_s_at 200 0.578022 Survival 1.77] Distant Metastasis Free 2.07 [0.96 - GSE11121 HG-U133A 214214_s_at 200 0.063933 Survival 4.49] MLRG Human 1.32 [1.06 - GSE9893 Overall Survival 19328 155 0.011484 21K V12.0 1.64] Distant Metastasis Free 0.81 [0.51 - GSE2034 HG-U133A 208910_s_at 286 0.354935 Survival 1.27] Distant Metastasis Free 1.04 [0.64 - GSE2034 HG-U133A 214214_s_at 286 0.878539 Survival 1.68] GSE1456- 1.49 [0.80 - Overall Survival HG-U133A 208910_s_at 159 0.207785 GPL96 2.79] GSE1456- 1.85 [0.79 - Disease Specific Survival HG-U133A 214214_s_at 159 0.155031 GPL96 4.34] GSE1456- 1.66 [0.89 - Relapse Free Survival HG-U133A 208910_s_at 159 0.110369 GPL96 3.11] GSE1456- 1.49 [0.72 - Overall Survival HG-U133A 214214_s_at 159 0.28609 GPL96 3.12] GSE1456- 1.58 [0.76 - Disease Specific Survival HG-U133A 208910_s_at 159 0.221318 GPL96 3.29] GSE1456- 1.90 [0.93 - Relapse Free Survival HG-U133A 214214_s_at 159 0.080311 GPL96 3.90] 1.44 [0.75 - GSE7378 Disease Free Survival U133AAofAv2 208910_s_at 54 0.275125 2.79] 1.62 [0.71 - GSE7378 Disease Free Survival U133AAofAv2 214214_s_at 54 0.254049 3.72] Distant Metastasis Free 0.86 [0.59 - E-TABM-158 HG-U133A 208910_s_at 117 0.406336 Survival 1.23] 0.94 [0.69 - E-TABM-158 Overall Survival HG-U133A 208910_s_at 117 0.6718 1.27] 0.94 [0.66 - E-TABM-158 Relapse Free Survival HG-U133A 214214_s_at 117 0.73798 1.35] 0.87 [0.58 - E-TABM-158 Disease Specific Survival HG-U133A 214214_s_at 117 0.489297 1.30] 0.94 [0.66 - E-TABM-158 Overall Survival HG-U133A 214214_s_at 117 0.73798 1.35] Distant Metastasis Free 0.91 [0.59 - E-TABM-158 HG-U133A 214214_s_at 117 0.668049 Survival 1.41] 0.94 [0.69 - E-TABM-158 Relapse Free Survival HG-U133A 208910_s_at 117 0.6718 1.27] 0.86 [0.61 - E-TABM-158 Disease Specific Survival HG-U133A 208910_s_at 117 0.377166 1.21] GSE3494- 1.22 [0.70 - Disease Specific Survival HG-U133A 208910_s_at 236 0.477552 GPL96 2.12] GSE3494- 1.25 [0.66 - Disease Specific Survival HG-U133A 214214_s_at 236 0.494525 GPL96 2.38] GSE4922- 1.39 [0.86 - Disease Free Survival HG-U133A 214214_s_at 249 0.174824 GPL96 2.25] GSE4922- 1.37 [0.89 - Disease Free Survival HG-U133A 208910_s_at 249 0.151466 GPL96 2.09] Distant Metastasis Free 1.28 [0.79 - GSE2990 HG-U133A 208910_s_at 125 0.310531 Survival 2.06] 0.78 [0.37 - GSE2990 Relapse Free Survival HG-U133A 214214_s_at 62 0.502492 1.63] 1.12 [0.78 - GSE2990 Relapse Free Survival HG-U133A 208910_s_at 125 0.536003 1.63] Distant Metastasis Free 1.54 [0.83 - GSE2990 HG-U133A 214214_s_at 125 0.169222 Survival 2.87] Distant Metastasis Free 0.82 [0.35 - GSE2990 HG-U133A 208910_s_at 54 0.638987 Survival 1.90] 1.28 [0.80 - GSE2990 Relapse Free Survival HG-U133A 214214_s_at 125 0.307875 2.06] Distant Metastasis Free 0.73 [0.31 - GSE2990 HG-U133A 214214_s_at 54 0.457043 Survival 1.69] 0.90 [0.44 - GSE2990 Relapse Free Survival HG-U133A 208910_s_at 62 0.784708 1.86] Distant Metastasis Free 1.11 [0.74 - GSE7390 HG-U133A 214214_s_at 198 0.618647 Survival 1.65] 1.11 [0.73 - GSE7390 Overall Survival HG-U133A 214214_s_at 198 0.624726 1.69] 1.10 [0.80 - GSE7390 Relapse Free Survival HG-U133A 208910_s_at 198 0.547065 1.52] Distant Metastasis Free 1.06 [0.72 - GSE7390 HG-U133A 208910_s_at 198 0.775386 Survival 1.55] 1.14 [0.81 - GSE7390 Relapse Free Survival HG-U133A 214214_s_at 198 0.444162 1.60] 1.05 [0.70 - GSE7390 Overall Survival HG-U133A 208910_s_at 198 0.818554 1.57] Supplementary Table S3. Datasets of C1QBP expression in lung cancer (Oncomine database). Normal Fold p- Rank Dataset Tumor (Cases) t-Test (Cases) change value (%) Squamous Cell Lung Wachi Lung (5) 1.838 4.106 0.003 6 Carcinoma (5) Large Cell Lung Carcinoma 4.39E- Hou Lung (65) 1.928 5.892 6 (19) 06 Squamous Cell Lung 2.32E- Lung (65) 1.867 7.139 8 Carcinoma (27) 08 4.16E- Lung (65) Lung Adenocarcinoma (45) 1.363 4.857 13 06 9.42E- Landi Lung (49) Lung Adenocarcinoma (58) 1.468 5.59 12 08 Su Lung (30) Lung Adenocarcinoma (27) 1.235 2.037 0.024 23 Okayama Lung (20) Lung Adenocarcinoma (226) 1.182 3.143 0.002 33 Supplementary Table S4. Survival analyses of C1QBP in lung cancer (PrognoScan database). COX p- DATASE HR [95% CI- SUBTYPE ENDPOINT ARRAY TYPE PROBE ID N VALU T low CI-upp] E jacob- Adenocarcinom Overall 1.10 [0.61 - 00182- HG-U133A 208910_s_at 82 0.75218 a Survival 1.98] CANDF jacob- Adenocarcinom Overall 1.21 [0.57 - 00182- HG-U133A 214214_s_at 82 0.61874 a Survival 2.59] CANDF jacob- Adenocarcinom Overall 1.60 [0.94 - 00182- HG-U133A 208910_s_at 79 0.08171 a Survival 2.71] HLM jacob- Adenocarcinom Overall 1.77 [1.00 - 00182- HG-U133A 214214_s_at 79 0.04994 a Survival 3.13] HLM jacob- Adenocarcinom Overall 10 0.74 [0.36 - 00182- HG-U133A 214214_s_at 0.41293 a Survival 4 1.53] MSK jacob- Adenocarcinom Overall 10 0.80 [0.48 - 00182- HG-U133A 208910_s_at 0.40605 a Survival 4 1.35] MSK Adenocarcinom Overall A_23_P37043 11 1.65 [0.93 - GSE13213 G4112F 0.08626 a Survival 4 7 2.91] Adenocarcinom Overall HG- 20 0.65 [0.21 - GSE31210 208910_s_at 0.45502 a Survival U133_Plus_2 4 2.03] Adenocarcinom Overall HG- 20 0.74 [0.21 - GSE31210 214214_s_at 0.64079 a Survival U133_Plus_2 4 2.63] Adenocarcinom Relapse Free HG- 20 1.52 [0.62 - GSE31210 214214_s_at 0.36443 a Survival U133_Plus_2 4 3.73] Adenocarcinom Relapse Free HG- 20 1.41 [0.63 - GSE31210 208910_s_at 0.40748 a Survival U133_Plus_2 4 3.18] jacob- Adenocarcinom Overall 17 0.97 [0.64 - HG-U133A 208910_s_at 0.90606 00182-UM a Survival 8 1.48] jacob- Adenocarcinom Overall 17 1.10 [0.69 - HG-U133A 214214_s_at 0.69053 00182-UM a Survival 8 1.75] Overall Novachip 0.93 [0.49 - GSE11117 NSCLC H200006536 41 0.82862 Survival human 34.5k 1.78] Overall HG- 11 0.82 [0.54 - GSE3141 NSCLC 208910_s_at 0.36701 Survival U133_Plus_2 1 1.26] Overall HG- 11 1.00 [0.66 - GSE3141 NSCLC 214214_s_at 0.99807 Survival U133_Plus_2 1 1.51] Overall 1.18 [0.78 - GSE14814 NSCLC HG-U133A 208910_s_at 90 0.43197 Survival 1.81] Disease 1.22 [0.76 - GSE14814 NSCLC Specific HG-U133A 208910_s_at 90 0.41344 1.97] Survival Disease 1.13 [0.75 - GSE14814 NSCLC Specific HG-U133A 214214_s_at 90 0.55358 1.70]